Catalent Collaborates with Minomic to Develop Prostate Cancer Treatment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Collaborates with Minomic to Develop Prostate Cancer Treatment


Catalent announced on Aug. 27 that it is collaborating with privately-held Australian biomarker research company, Minomic International Limited, to develop MIL-38, an antibody drug conjugate (ADC) for prostate cancer therapy. Under the agreement, Catalent will initially produce the antibody for a clinical study with a view to larger scale production, subject to a successful outcome.

The antibody production project incorporates Catalent’s proprietary GPEx technology, which creates stable, high-yielding mammalian cell lines typically getting drug development projects to clinic in one-third the time of traditional approaches, Catalent reports. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial scale production.

If the initial clinical study proves successful, the antibody will be produced at Catalent’s biomanufacturing facility in Madison, WI.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here